Skip to main content
13 July 2026
Last updated: Monday 13 July 2026

User account anon menu

  • Login
  • Register and subscribe
Home
  • Home
  • News
    • News
    • Appointments
    • Events
  • About MedNous
    • Who We Are
    • Editorial Board
    • Editorial Policy
  • Research Directory
    • Research Directory
    • Organisations
    • Interviewees
    • Terms
    • Topics
  • Contact Us
    • Contact Form
Menu

Breadcrumb

  1. Home
  2. A Good Beginning In The Perilous Biotech Business

A good beginning in the perilous biotech business

Tuesday 26 October 2010
Interviewee/Contributor
Ingmar Hoerr
Organisation
CureVac GmbH

---Subscribe to MedNous to access this article---

Prostate cancer
mRNA - Messenger Ribonucleir Acid
Vaccine
Cancer (Oncology)

Select a News Category

  • Clinical Research
  • Company News
  • Finance, Grants, Deals
  • IPR & Legal
  • Regenerative Medicine
  • Regulation & Policy
  • Research & University News

Recent Appointments

Evotec names head of in silico and AI

Saturday 20 June 2026

Forbion promotes senior officers, appoints operating partner

Saturday 20 June 2026

Specialist CDMO Ardena appoints CSO

Saturday 20 June 2026

CellaVision names CEO

Saturday 20 June 2026

FundaMental Pharma names CMO to lead depression candidate

Saturday 20 June 2026
View more appointments

Looking for more?

MedNous covers medical news and more. See more in our various site sections.

  • News
  • Industry appointments
  • Events
  • Research directory
  • Subscribe

Footer

  • Privacy policy

© 2026 Evernow Publishing Ltd.

  • Home
  • News
    • News
    • Appointments
    • Events
  • About MedNous
    • Who We Are
    • Editorial Board
    • Editorial Policy
  • Research Directory
    • Research Directory
    • Organisations
    • Interviewees
    • Terms
    • Topics
  • Contact Us
    • Contact Form